Originally pusblished on Substack
This week’s new material: labs returning very different numbers on what was reported as the same product, a telehealth company staging a peptide line, warnings of shipping delays ahead of the Shenzhen summit, and tighter customs scrutiny. The HHS peptide policy we covered last week is a follow-up, further down. Ten items follow, with what the evidence does and does not show. Nothing here is medical advice or a recommendation to use any compound.
1. Same sample, different labs, very different numbers
Krysia, who writes a Substack that digs into third-party peptide testing, documented several cases this week where labs disagreed on the same product. The credit for surfacing these goes to her work and to the labs willing to publish their results. These are anecdotal, vendor-submitted samples, not controlled comparisons, and separate vials can differ. In one case, described as apparently the same batch of a 10 mg retatrutide product, one lab reported 3.98 mg at 36.44% purity, a second reported about 7.7 mg at about 67.3% (two runs, 67.301% and 67.319%), and a third reported 11.26 mg at 98.183%. Janoshik said the simplest explanation for its gap with the second lab was “sample difference”; the first lab declined to discuss. In another case, two labs tested separate vials from the same 10 mg eloralintide kit: one reported 99.74% purity and 10.09 mg, the other 67.8% and 12.1 mg. The second lab stands by its result, citing an extra chromatogram peak that barely registered at 220 nm but showed strongly at 280 nm, which it says it has not yet identified; it says it ruled out two candidate explanations, and no response from the first lab was available. Methods also differ in what “purity” means: one lab does not report blend purity at all because overlapping peaks can hide impurities, another reports combined peak area and says it is “not absolute mass purity,” and one lab found the TB-500 fragment co-eluted with another component. The takeaway: “99%” on a certificate usually means 99% of detected peak area at one wavelength, not 99% of the vial, and a single certificate cannot settle quality. A separate site reports several popular labs are not accredited (ISO/IEC 17025) for peptide assays; it has vendor ties, so verify before citing.
Sources: Krysia (Substack) and her follow-up notes, ChemVerify (commercial ties)
2. Telehealth moves in: Hims & Hers stages a peptide line
On its Aug 10 earnings call, Hims & Hers said it planned to sell compounded peptides by the end of 2026 in phases: sermorelin, glutathione and an existing product first, and the six committee-recommended peptides only after FDA action. The day after HHS acted, its Oct 29 release described a “Peptides+” preview with a waitlist, listing sermorelin, glutathione, B12, NAD+ and L-carnitine, with BPC-157 and TB-500 to follow “when allowable.” The release gives no launch date or pricing, says treatment would come through independent providers and licensed pharmacies, and itself notes that published studies are limited. Becker’s reports the company is running stability testing on BPC-157 at a California facility. As of this week, this is a waitlist and a plan, not a launch.
Sources: Hims & Hers release (company, promotional), Becker’s Hospital Review
3. Shenzhen summit: shipping delays are warned, but no export restriction is confirmed
The APEC Economic Leaders’ Meeting is scheduled for Nov 18 to 19 in Shenzhen. A peptide sourcing vendor’s advisory says freight partners expect “enhanced security measures and stricter cargo inspections” in Shenzhen-area logistics hubs before and during the summit, with delays it calls impossible to predict. That advisory does not mention any government restriction on peptide exports, and I found no confirmed Chinese government export restriction on peptides. Separate social posts relay vendor warnings of a longer shipping disruption starting in late September; I could not verify those. Treat this as a logistics warning, not a policy change.
Sources: APEC China 2026 (Wikipedia), vendor advisory (commercial source)
4. Customs and enforcement are tightening on peptide shipments
On Nov 5, NL Times (citing RTL Nieuws and BNR) reported that Dutch Customs stopped “hundreds of shipments” containing peptides through September, mostly by courier, while RTL identified 203 illegal online pharmacies, more than half under six months old, with products mainly supplied from China. Earlier this year, U.S. Customs and Border Protection reported a Cincinnati interdiction of roughly 5,000 mis-manifested peptide shipments from China, per a secondary summary of the CBP release (exact dates should be confirmed against the primary release). Neither report describes Chinese export controls.
Sources: NL Times, ChemVerify (secondary, commercial ties)
5. A large preprint finds wide variability in marketed research peptides
A preprint by Mendias and Awan (Apr 24, 2026; not peer reviewed) analyzed public third-party testing data from Finnrick Analytics: 14 peptides, 6,285 analyzed samples from 203 companies, tested between December 2024 and April 2026. Depending on the acceptance standard, 41.6% to 71.1% of samples failed basic criteria. Median measured content was 101.8% of label claim, but TB-500 had the lowest median purity (97.29%) and the highest identity failure rate (10.0%), and quality varied more between vendors than between peptides. Endotoxin data existed for under 4% of samples, and 15% of those showed measurable endotoxin. The authors caution the data are voluntary submissions, not a representative sample, and the failure rates are likely a lower bound.
Source: Preprints.org 202604.1748
6. A new orthopaedic review: preclinical promise, thin human data
A narrative review in the Journal of the American Academy of Orthopaedic Surgeons (online Oct 27) covers BPC-157, thymosin beta-4 and TB-500, searching PubMed, EMBASE and Scopus through June 2026. BPC-157 has the largest musculoskeletal preclinical literature, mostly in small animals, while the human musculoskeletal evidence is one small, retrospective, uncontrolled case series. Thymosin beta-4’s musculoskeletal evidence is in vitro and rodent only, and TB-500 is a seven-amino-acid fragment often confused with full-length thymosin beta-4, with no validated equivalence. The authors flag identity, purity, sterility and consistency concerns for commercial products and conclude routine clinical use cannot currently be recommended.
Source: PubMed 42937313
7. Follow-up: the HHS interim policy on six peptides, one week on
As covered last week, the Department of Health and Human Services filed an interim policy on Oct 28 (scheduled for Federal Register publication Oct 30) covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound these six while FDA works on its 503A bulks list. The policy is interim and non-final, signed by the HHS Secretary rather than issued by FDA, and HHS says it may revisit it if a safety signal or quality problem appears.
Sources: AJMC, Foley & Lardner
8. What the policy requires, and what it is not
Per a law-firm summary, enforcement discretion applies only if conditions are met: the bulk substance comes from an FDA-registered facility with a valid certificate of analysis, the original manufacturer is FDA-registered and CGMP-compliant, adverse events go to MedWatch, the product has a single active ingredient, and labeling states “This is a compounded drug product. Not for resale.” The policy does not add the peptides to the 503A bulks list and is not FDA approval of any compounded product. A formal listing would need notice-and-comment rulemaking, which can take months to years. FDA does not review compounded products for safety, effectiveness or quality before marketing.
Sources: Foley & Lardner, BioXconomy
9. The policy departs from FDA staff advice, and a petition pushes back
In July, FDA’s Pharmacy Compounding Advisory Committee narrowly recommended six of seven nominated peptides after the panel was reshaped; some members reportedly had industry ties. FDA’s career scientists recommended against, citing poorly characterized structures, limited safety data, contamination risk, possible immune reactions from peptide aggregation and little data on combinations. HHS says circumstances changed and calls CDER’s concerns “inferential/mechanistic rather than based on observed harm,” but as of BioXconomy’s reporting the evidence HHS cited had not been published. The Partnership for Safe Medicines petitioned FDA (reported Oct 26) to disregard the vote. Written comments on the HHS policy are due two weeks after publication, which one law-firm summary puts at Nov 13.
Sources: pharmaphorum, BioXconomy, AJMC, PeptideLaws
10. Approved peptide drugs keep moving: NICE expands Imcivree, GLP-1 pipeline advances
Rhythm Pharmaceuticals announced Nov 4 that NICE issued positive guidance for Imcivree (setmelanotide) for adults with genetically confirmed Bardet-Biedl syndrome in England, Wales and Northern Ireland, expanding a May 2024 recommendation for ages 6 to 17; children 2 to 5 are already funded through NHS England. This comes from a company press release that says it is intended for investors, cites no trial numbers and does not quote NICE, so check NICE’s own document. It is a regulated drug for a rare genetic condition, a contrast with the unapproved research peptides above. On incretins, per an industry aggregator (check primary sources), retatrutide’s TRIUMPH-2 showed 20.8% weight loss at 80 weeks on 12 mg versus 4.0% on placebo, with Lilly targeting a filing in Q1 2027; survodutide’s SYNCHRONIZE-2 reported 13.1% versus 3.1% at 76 weeks; orforglipron has a positive CHMP opinion with the European Commission decision pending.
Sources: Rhythm Pharmaceuticals release (company), Life Science Daily
Dates to watch: Nov 13 (HHS comment deadline, per one law-firm summary), Nov 14 to 17 (ObesityWeek), Nov 18 (NICE orforglipron appraisal expected), Nov 18 to 19 (APEC Shenzhen). No published date: FDA’s CagriSema decision and any bulks-list rulemaking.
Evidence note: Items 2 to 4 and 7 to 9 are policy, business and logistics reporting; item 1 is anecdotal, not evidence about whether these compounds work. Item 6 is the only peer-reviewed abstract verified this week; item 5 is a preprint. Company press releases are labeled as promotional.
Credits: item 1 draws on Krysia’s Substack reporting and the lab results she compiled (Janoshik, Freedom Diagnostics, Chromate, BT Labs, Vanguard, Testides, Amino Metrics). Item 5 is the work of Mendias and Awan using public data from Finnrick Analytics. Item 6 is the JAAOS review authors’ work. Item 2 draws on Hims & Hers’ own release and Becker’s Hospital Review. Item 4 draws on NL Times (reporting by RTL Nieuws and BNR). Items 7 to 9 draw on AJMC, Foley & Lardner, BioXconomy, pharmaphorum and PeptideLaws.
